Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB800 vs Actemra in healthy volunteers
NCT06262477Phase 1Completed
- Sponsor
- Biogen
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of bat1806 (2 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Serum Concentration of Tocilizumab at 57 days, Area Under the Concentration-Time Curve From Time Zero to Infinity at 57 days and 1 more. Started Jan 2024; status: completed.
02
Drugs
bat1806
Beyond the preview
Go deeper on NCT06262477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06262477.